Loading
A phase 2 trial of Selinexor, Dexamethasone, Bortezomib in multiple myeloma, run by Karyopharm Therapeutics Inc, now recruiting.
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. is a phase 2 interventional study registered as NCT04414475 by Karyopharm Therapeutics Inc, with 127 participants planned, started 2020-07-01 and due to reach its primary completion in 2028-01. Interventions recorded: Selinexor, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma, Refractory. No results are recorded here; the registry entry is the source.
Shares Karyopharm Therapeutics, Selinexor, Bortezomib, Dexamethasone.
Shares Karyopharm Therapeutics, Selinexor, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.